Learn from Prof. Papadopoulou as she highlights challenges in identifying EoE in pediatric patients and the consequences of delayed diagnosis.
Use this educational tool to explore the daily burden of loss of smell for patients with CRSwNP.

Professor Klaus Rabe delves into the intricate inflammatory pathways and cellular mechanisms that drive the development and progression of COPD.

Dr. Stella Lee explores the past, present and future implementation of guidelines into daily practice

Learn about the significant burden that patients with EoE experience, and the role of type 2 inflammation in this chronic, progressive disease.

Learn about the importance of assessing key disease domains in EoE by focusing on symptoms, QoL, endoscopy, and histology.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr Amy Paller reviews the increased risk of atopic and nonatopic comorbidities associated with atopic dermatitis and discusses the potential of early intervention to mitigate their development.

Learn about the role of type 2 inflammation in the burden and pathophysiology of severe asthma in pediatric patients

In this video soundbite from the EAACI 2025 symposium, Dr. Brian Lipworth discusses that co-existing type 2 inflammatory diseases are common in patients with CRSwNP & increasing severity of asthma is associated with higher severity of CRS and prevalence of nasal polyps. Additionally, he explains that patient burden is substantially greater when asthma and CRSwNP are co-existing.

Drs. Bob Geng and Lawrence Eichenfield highlight a multidisciplinary team approach to patient-centered care in diseases with type 2 inflammation
This chapter highlights how a food bolus impaction may be the initial manifestation of a patient with EoE masked by adaptive eating behavior.

In this video soundbite from the EAACI 2025 symposium, Dr. Philippe Gevaert explains how biologic options for uncontrolled CRSwNP are increasing, and phase 3 studies of approved biologics show improved outcomes and decreased SCS use/surgery in patients with CRSwNP. Additionally, he explains how biologics targeting type 2 inflammatory pathophysiology potentially improve outcomes for eligible patients with co-existing CRSwNP and asthma.